Trial Profile
A Phase 1b Study of Talimogene Laherparepvec (T-VEC) in Combination With Chemotherapy or Endocrine Therapy in Patients With Metastatic, Unresectable, or Locoregionally Recurrent HER2-negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Carboplatin (Primary) ; Exemestane (Primary) ; Fulvestrant (Primary) ; Gemcitabine (Primary) ; Letrozole (Primary) ; Paclitaxel (Primary) ; Talimogene laherparepvec (Primary) ; Tamoxifen (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 11 May 2023 Planned End Date changed from 30 Apr 2024 to 30 Apr 2025.
- 11 May 2023 Planned primary completion date changed from 30 Apr 2024 to 30 Apr 2025.